OrganiGram Holdings Inc
TSX:OGI

Watchlist Manager
OrganiGram Holdings Inc Logo
OrganiGram Holdings Inc
TSX:OGI
Watchlist
Price: 2.64 CAD -4.35% Market Closed
Market Cap: 354.6m CAD

EV/EBITDA
Enterprise Value to EBITDA

-5.7
Current
-2.3
Median
13.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5.7
=
Enterprise Value
402.4m CAD
/
EBITDA
-70.3m CAD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CA
OrganiGram Holdings Inc
TSX:OGI
Average EV/EBITDA: 438.9
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.7
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
12.4
2-Years Forward
EV/EBITDA
8.8
3-Years Forward
EV/EBITDA
6.9